Fox Jennifer A. — SEC insider filings
SEC reporting owner CIK 1841557. 18 insider filings on record with FilingPulse; latest filed 2026-09-03.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2021-02-12 to 2026-09-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Apogee Therapeutics, Inc. (APGE) | Director | 4 | — | — | 7 |
| PROKIDNEY CORP. (PROK) | Director | 6 | — | — | 7 |
| Nuvation Bio Inc. (NUVB) | Chief Financial Officer | 4 | — | — | 5 |
| Zenas BioPharma, Inc. (ZBIO) | See Remarks | 4 | — | — | 5 |
Insider filings — Fox Jennifer A.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Apogee Therapeutics, Inc. (APGE) | Disposition to issuer (D): 34,824 · Disposition to issuer (D): 10,370 (derivative) · Disposition to issuer (D): 14,461 (derivative) · Disposition to issuer (D): 7,657 (derivative) | EDGAR |
| 2026-06-17 | 4 | Zenas BioPharma, Inc. (ZBIO) | Grant/award (A): 1,592 @ $13.35 · Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 7,657 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | PROKIDNEY CORP. (PROK) | Grant/award (A): 135,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 14,461 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Zenas BioPharma, Inc. (ZBIO) | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | PROKIDNEY CORP. (PROK) | Grant/award (A): 125,862 (derivative) @ $0 | EDGAR |
| 2024-12-18 | 4 | Zenas BioPharma, Inc. (ZBIO) | Grant/award (A): 8,125 (derivative) @ $0 | EDGAR |
| 2024-09-16 | 4 | Zenas BioPharma, Inc. (ZBIO) | Grant/award (A): 155,000 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | PROKIDNEY CORP. (PROK) | Grant/award (A): 9,535 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 10,370 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | PROKIDNEY CORP. (PROK) | Grant/award (A): 62,558 (derivative) @ $0 | EDGAR |
| 2023-07-13 | 4 | PROKIDNEY CORP. (PROK) | Grant/award (A): 46,632 (derivative) @ $0 · Grant/award (A): 42,515 (derivative) @ $0 | EDGAR |
| 2023-03-02 | 4 | Nuvation Bio Inc. (NUVB) | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2022-09-22 | 4 | PROKIDNEY CORP. (PROK) | Grant/award (A): 129,370 (derivative) @ $0 | EDGAR |
| 2022-08-31 | 4 | Nuvation Bio Inc. (NUVB) | Grant/award (A): 480,000 (derivative) @ $0 | EDGAR |
| 2022-03-02 | 4 | Nuvation Bio Inc. (NUVB) | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2021-02-12 | 4 | Nuvation Bio Inc. (NUVB) | Grant/award (A): 398,935 (derivative) · Grant/award (A): 558,506 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-02-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1841557 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs